🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Canada / NCT07346690
Starting soon Phase 1

A Study Testing the Effects of Different THC Doses on Psychological and Biological Function

NCT07346690 · tracked via the Priya Life Science Canada tracker
Phase
Phase 1
Started
2026-02-01
Last updated
2026-01-16

Condition(s) studied

Evaluate PK ProfileEvaluate PD ProfileHealthy AdultsSafety and Tolerability in Healthy Volunteers

Investigational drug(s) / intervention(s)

AVCN319301b (6mg)AVCN319301b (9mg)AVCN319301b (15mg)Placebo

AVCN319301b (6mg): AVCN319301b is a standardized oral capsule containing a precise dose of Δ9-THC.

AVCN319301b (9mg): AVCN319301b is a standardized oral capsule containing a precise dose of Δ9-THC.

AVCN319301b (15mg): AVCN319301b is a standardized oral capsule containing a precise dose of Δ9-THC.

Placebo: The matched placebo is an oral capsule identical in appearance to the active study drug and contains the same non-medicinal ingredients but no Δ9-THC. It is manufactured to match the active capsules in size, color, taste, and packaging to maintain blinding for participants and study staff.

Study summary

The goal of this clinical trial is to learn how a investigational medicinal product (THC) affects psychological and physical responses in healthy adults with prior cannabis use experience. The main questions it aims to answer are:

\- How do different dose levels of the investigational medicinal product (THC) influence short-term subjective and physiological responses?

Researchers will compare three dose levels of the study drug to a placebo (a look-alike substance with no active ingredient) to see how responses vary across sessions.

Participants will:

* Attend four in-person study visits, each involving a single dose of either the study drug or placebo
* Complete questionnaires about their moment-to-moment experiences
* Have their heart rate, blood pressure, and other physical measures monitored
* Undergo serial blood sampling to measure circulating biomarkers

Eligibility

Sex
ALL
Min age
18 Years
Max age
55 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Adults aged 18-55 * No major medical or psychiatric conditions * At least one previous, well-tolerated experience with cannabis * Not currently pregnant or breastfeeding Exclusion Criteria: * Family history (first- or second-degree relatives) of bipolar disorder, psychosis, or schizophrenia * Significant negative reaction to cannabis in the past or known allergy to cannabis products * Currently using recreational drugs

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University of Calgary, Heritage Medical Research Building Calgary Alberta

More University of Calgary trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07346690 on ClinicalTrials.gov ↗ ← All trials in Canada